Tenvir
Developed to mitigate viral replication to support immune CD4 counts and target hepatitis B viral liver safety.
- Categories
- HIV Management · Antivirals · Hepatitis Treatment
- Active ingredient
- Tenofovir Disoproxil
- Route
- Oral use
- Form
- Tablet
- Strengths
- 300mg
Prescription and consultation requirements for Tenvir vary by destination and are determined by the fulfilment partner.
Tenvir details
- Alternative names
- tenofovir
- Therapeutic class
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Pharmacological class
- NRTI
- Contraindications
- severe renal impairment; hypersensitivity to tenofovir
- Minor side effects
- nausea; headache; fatigue
- Moderate side effects
- renal impairment; bone density decrease; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Acyclovir; Didanosine; NSAIDs
- Age restrictions
- Approved for patients over two years of age and adults.
Serious side effects
lactic acidosis, requires immediate medical attention; severe acute hepatitis B flare, requires immediate medical attention
Patient summary
developed to mitigate viral replication to support immune CD4 counts and target hepatitis B viral liver safety.
Mechanism of action
Inhibits viral reverse transcriptase and DNA polymerase, leading to termination of the viral DNA chain.
Pregnancy and breastfeeding
TGA Category B: Safety established. Essential therapy component. Breastfeeding: Consult a doctor.